

Sarah P Hudson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5610765/publications.pdf>

Version: 2024-02-01

50
papers

2,206
citations

394286

19
h-index

214721

47
g-index

52
all docs

52
docs citations

52
times ranked

3471
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of varying dextran oxidation levels on the inhibitory activity of a bacteriocin loaded injectable hydrogel. <i>Drug Delivery and Translational Research</i> , 2023, 13, 308-319.	3.0	5
2	Balanced lipase interactions for degradation-controlled paclitaxel release from lipid cubic phase formulations. <i>Journal of Colloid and Interface Science</i> , 2022, 607, 978-991.	5.0	4
3	Synergistic antimicrobial interactions of nisin A with biopolymers and solubilising agents for oral drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 171, 29-38.	2.0	6
4	NUIG4: A biocompatible pcu metal-organic framework with an exceptional doxorubicin encapsulation capacity. <i>Journal of Materials Chemistry B</i> , 2022, 10, 1378-1385.	2.9	4
5	The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties. <i>International Journal of Pharmaceutics</i> , 2022, 621, 121806.	2.6	3
6	Single versus double occupancy solid lipid nanoparticles for delivery of the dual-acting bacteriocin, lacticin 3147. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 199-210.	2.0	6
7	Long acting injectables for therapeutic proteins. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 217, 112644.	2.5	3
8	Citric acid functionalized nitinol stent surface promotes endothelial cell healing. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, 109, 1549-1559.	2.1	4
9	Preparation, stabilisation, isolation and tableting of valsartan nanoparticles using a semi-continuous carrier particle mediated process. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120199.	2.6	4
10	Pharmaceutical design of a delivery system for the bacteriocin lacticin 3147. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1735-1751.	3.0	10
11	Drug delivery for fighting infectious diseases: a global perspective. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1316-1322.	3.0	6
12	Pre-formulation and delivery strategies for the development of bacteriocins as next generation antibiotics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 149-163.	2.0	21
13	Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs. <i>Molecular Pharmaceutics</i> , 2021, 18, 3777-3794.	2.3	4
14	Stent conditioned media for in vitro evaluation of hydrophobic stent coatings. <i>Toxicology in Vitro</i> , 2021, 76, 105212.	1.1	1
15	Candidates for smart cardiovascular medical device coatings: A comparative study with endothelial and smooth muscle cells. <i>European Journal of Pharmacology</i> , 2021, 910, 174490.	1.7	7
16	Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 193, 111120.	2.5	28
17	Tuning the strength and swelling of an injectable polysaccharide hydrogel and the subsequent release of a broad spectrum bacteriocin, nisin A. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4029-4038.	2.9	49
18	The impact of endogenous gastrointestinal molecules on the dissolution and precipitation of orally delivered hydrophobic APIs. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 677-688.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor. <i>Journal of Colloid and Interface Science</i> , 2020, 573, 176-192.	5.0	17
20	Drug Loading and Dissolution Properties of Dalcetrapibâ€“Montmorillonite Nanocomposite Microparticles. <i>Organic Process Research and Development</i> , 2020, 24, 977-987.	1.3	6
21	Overcoming the Common Ion Effect for Weakly Basic Drugs: Inhibiting the Crystallization of Clofazimine Hydrochloride in Simulated Gastrointestinal Media. <i>Crystal Growth and Design</i> , 2019, 19, 1599-1609.	1.4	4
22	Protecting bactofencin A to enable its antimicrobial activity using mesoporous matrices. <i>International Journal of Pharmaceutics</i> , 2019, 558, 9-17.	2.6	20
23	Carrier particle mediated stabilization and isolation of valsartan nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 554-563.	2.5	14
24	Mesoporous matrices for the delivery of the broad spectrum bacteriocin, nisin A. <i>Journal of Colloid and Interface Science</i> , 2019, 537, 396-406.	5.0	33
25	Promotion of Mefenamic Acid Nucleation by a Surfactant Additive, Docusate Sodium. <i>Crystal Growth and Design</i> , 2019, 19, 591-603.	1.4	15
26	Heterogeneous Crystallization of Fenofibrate onto Pharmaceutical Excipients. <i>Crystal Growth and Design</i> , 2018, 18, 2151-2164.	1.4	14
27	Experimental Study on the Influence of Excipients on the Heterogeneous Crystallization and Dissolution Properties of an Active Pharmaceutical Ingredient. <i>Crystal Growth and Design</i> , 2018, 18, 338-350.	1.4	18
28	Dependence of Heterogeneous Nucleation on Hydrogen Bonding Lifetime and Complementarity. <i>Crystal Growth and Design</i> , 2018, 18, 7158-7172.	1.4	19
29	Delivery of a hydrophobic drug into the lower gastrointestinal system via an endogenous enzyme-mediated carrier mechanism: An in vitro study. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 12-19.	2.0	11
30	Investigating the effects of amphipathic gastrointestinal compounds on the solution behaviour of salt and free base forms of clofazimine: An in vitro evaluation. <i>International Journal of Pharmaceutics</i> , 2018, 552, 180-192.	2.6	6
31	The heterogeneous crystallization of a novel solvate of clozapine base in the presence of excipients. <i>CrystEngComm</i> , 2018, 20, 4370-4382.	1.3	13
32	Influence of Process Parameters on the Heterogeneous Nucleation of Active Pharmaceutical Ingredients onto Excipients. <i>Organic Process Research and Development</i> , 2017, 21, 559-570.	1.3	13
33	Stepwise Use of Additives for Improved Control over Formation and Stability of Mefenamic Acid Nanocrystals Produced by Antisolvent Precipitation. <i>Crystal Growth and Design</i> , 2017, 17, 454-466.	1.4	20
34	Size and Shape Control of Micron-Sized Salicylic Acid Crystals during Antisolvent Crystallization. <i>Organic Process Research and Development</i> , 2017, 21, 1732-1740.	1.3	19
35	Preparation and characterization of amorphous ciprofloxacin-amino acid salts. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 121, 73-89.	2.0	38
36	Carrier particle design for stabilization and isolation of drug nanoparticles. <i>International Journal of Pharmaceutics</i> , 2017, 518, 111-118.	2.6	15

#	ARTICLE	IF	CITATIONS
37	Role of Biorelevant Dissolution Media in the Selection of Optimal Salt Forms of Oral Drugs: Maximizing the Gastrointestinal Solubility and in Vitro Activity of the Antimicrobial Molecule, Clofazimine. ACS Omega, 2017, 2, 8969-8981.	1.6	20
38	Recyclable SERS substrates based on Fe ₂ O ₃ @Ag hybrid hollow microspheres with crumpled surfaces. New Journal of Chemistry, 2016, 40, 5238-5244.	1.4	11
39	Investigation into the Solid and Solution Properties of Known and Novel Polymorphs of the Antimicrobial Molecule Clofazimine. Crystal Growth and Design, 2016, 16, 7240-7250.	1.4	21
40	Investigation of the Particle Growth of Fenofibrate following Antisolvent Precipitation and Freeze-Drying. Crystal Growth and Design, 2015, 15, 5213-5222.	1.4	24
41	Thermodynamics of fenofibrate and solubility in pure organic solvents. Fluid Phase Equilibria, 2014, 367, 143-150.	1.4	36
42	Investigation of the Solid-State Polymorphic Transformations of Piracetam. Crystal Growth and Design, 2012, 12, 6223-6233.	1.4	37
43	Enhancement and restriction of chain motion in polymer networks. International Journal of Pharmaceutics, 2012, 430, 34-41.	2.6	10
44	Injectable in situ cross-linking hydrogels for local antifungal therapy. Biomaterials, 2010, 31, 1444-1452.	5.7	126
45	A Nanoporous Reactor for Efficient Proteolysis. Chemistry - A European Journal, 2008, 14, 151-157.	1.7	76
46	Proteins in Mesoporous Silicates. Angewandte Chemie - International Edition, 2008, 47, 8582-8594.	7.2	622
47	The biocompatibility of mesoporous silicates. Biomaterials, 2008, 29, 4045-4055.	5.7	503
48	Proteins in Mesoporous Silicates. ACS Symposium Series, 2008, , 49-60.	0.5	5
49	Adsorption and Activity of a Domoic Acid Binding Antibody Fragment on Mesoporous Silicates. Journal of Physical Chemistry B, 2006, 110, 18703-18709.	1.2	31
50	Methodology for the Immobilization of Enzymes onto Mesoporous Materials. Journal of Physical Chemistry B, 2005, 109, 19496-19506.	1.2	176